Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Cash from Operations (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Cash from Operations for 13 consecutive years, with 9789000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 8.66% year-over-year to 9789000.0, compared with a TTM value of 9721000.0 through Dec 2025, down 140.13%, and an annual FY2025 reading of 9721000.0, down 140.13% over the prior year.
  • Cash from Operations was 9789000.0 for Q4 2025 at Tandem Diabetes Care, up from 8264000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 34144000.0 in Q3 2021 and bottomed at 18326000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 7225850.0, with a median of 7582500.0 recorded in 2022.
  • The sharpest move saw Cash from Operations tumbled 232.8% in 2023, then soared 48589.09% in 2024.
  • Year by year, Cash from Operations stood at 19635000.0 in 2021, then plummeted by 70.36% to 5820000.0 in 2022, then tumbled by 223.99% to 7216000.0 in 2023, then skyrocketed by 248.52% to 10717000.0 in 2024, then fell by 8.66% to 9789000.0 in 2025.
  • Business Quant data shows Cash from Operations for TNDM at 9789000.0 in Q4 2025, 8264000.0 in Q3 2025, and 9496000.0 in Q2 2025.